Profitelligence Profitelligence · Filing Ledger Open HALO research →

Form 8-K · Current Report · Filed 2026-07-02

Halozyme Therapeutics Announces Departure of COO

On June 30, 2026, Halozyme Therapeutics, Inc.

Filer
Halozyme Therapeutics Inc. HALO · NASDAQ
Filed
Accession
0001159036-26-000088
CIK
0001159036
Signal
Medium impactHealthcare

Details

announced the departure of Cortney Caudill, its Senior Vice President and Chief Operating Officer. The company thanked Ms. Caudill for her contributions during her tenure.

Items reported

Item events

Reported Item

COO Resignation

Market reaction

Close before filing

$77.01

Next session

+4.9%

Since filing

+43.2%

Latest close

$110.24

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from HALO reporting the same item, with the next session's move:

Halozyme Announces New $1 Billion Share Repurchase Program and Reports Q1 2026 Results+10.6%
Halozyme Therapeutics Holds Annual Meeting of Stockholders-3.4%
Halozyme Appoints New Chief Financial Officer+1.4%
Halozyme Therapeutics Amends Bylaws to Revise Director Removal and Meeting Actions-3.2%
Halozyme Therapeutics Appoints David Ramsay as Interim CFO-4.2%

Insider tape

Within 45 days of this filing, HALO insiders reported 20 Form 4 transactions — net selling of $1.3M.

Full HALO insider history →

About Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another HALO filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts